

SLR:slr 07/27/04 296693.doc  
PATENT

Attorney Reference Number 4239-62631-01  
Application Number 09/634,369

### Remarks

Claims 28 and 33-40 were pending. Claims 28 and 33 were amended. Claims 41-58 were added. No claims were cancelled. Therefore, claims 28 and 33-58 are now pending.

Support for the amendments to claims 28 and 33 (and the corresponding new dependent claims 41-58) can be found on page 9, lines 8-18; page 35, lines 7-8; and page 36, lines 14-24 of the specification. No new matter is introduced by these amendments.

No amendments made herein were made to distinguish the prior art.

During telephone conversations with the examiner on May 27, 2004 and July 23, 2004, the following issues were discussed.

First, the examiner requested that Applicants submit data showing the *in vivo* effect of epoxyeicosatrienoic acids (EETs) on cell death. Enclosed herein is a pre-print of an article accepted for publication by Circulation Research (Seubert *et al.*, Exhibit A), demonstrating that hearts from transgenic mice that overexpress CYP2J2 have improved postischemic recovery of left ventricular function compared to normal hearts after 20 minutes of ischemia and 40 minutes of reperfusion. CYP2J2 is a cytochrome P450 epoxygenase that metabolizes arachidonic acid to EETs. These EETs reduce the effects of hypoxia-reoxygenation *in vivo*.

Second, the examiner indicated that the term "analogs" in claims 28 and 33 was too broad, and suggested amending the claims to include the analogs listed on page 9. Although Applicants disagree, in order to expedite prosecution, claims 28 and 33 were amended to include the analogs listed on page 9, lines 8-18.

Third, the examiner suggested amending the term "preventing" in claim 28 to "reducing" or "minimizing." Applicants have amended claim 28 as suggested by the examiner.

SLR:slr 07/27/04 296693.doc  
PATENT

Attorney Reference Number 4239-62631-01  
Application Number 09/634,369


In view of the data showing that EETs reduce the effects of hypoxia-reoxygenation *in vivo*, and the amendments to claims 28 and 33, Applicants request that a Notice of Allowance be issued.

If any matters remain before a notice of allowance is issued, the examiner is invited to telephone the undersigned.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

  
Sherce Lynn Kybak, Ph.D.  
Registration No. 47,913

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446